BLRX Stock News 2.01 05/13/2014 16:33:56 Biolinerx Ltd (BLRX

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biolinerx Ltd (BLRX) 2.01 $BLRX

Update on BioLineRx's BL-8040 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 5:10PM CDT
BioLineRx announced that Prof. Arnon Nagler was given the final regulatory approval to evaluate BL-8040 in a phase I/II study for the treatment of CML.

BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment
Business Wire - Thu Apr 10, 6:01AM CDT
BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study. BioLineRx is currently developing BL-8040 in a Phase 2 study for treating acute myeloid leukemia (AML), and in a Phase 1 study for stem cell mobilization, as a pre-treatment for stem cell transplantation. The Company has received orphan drug designation for both these indications.

IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day.

ChemoCentryx (CCXI) Jumps: Stock Rises 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:51AM CDT
ChemoCentryx, Inc. was a big mover last session, as its shares rose nearly 10% on the day.

BioLineRx Reports Narrower 2013 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 9:20AM CDT
BioLineRx reported full year 2013 loss of 8 cents per share, narrower than the 2012 loss of 12 cents per share.

BioLineRx Reports Year End 2013 Financial Results
Business Wire - Mon Mar 17, 7:02AM CDT
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2013.

BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 in Immunotherapy
Business Wire - Fri Mar 14, 6:00AM CDT
--- Top-line results from both trials expected in next 9-12 months -

Pipeline Update at BioLineRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:50PM CDT
BioLineRx announced the successful completion of the single administration, dose-escalation stage of the ongoing phase I/II study on BL-7010

IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.

BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014
Business Wire - Tue Mar 11, 6:01AM CDT
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014, before the U.S. markets open.

BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment
Business Wire - Mon Mar 10, 6:00AM CDT
--BL-7010 now advancing to repeated administration part of study; results expected mid 2014

BioLineRx Closes $24.1 Million Underwritten Public Offering of its American Depositary Shares
Business Wire - Fri Mar 07, 11:00AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public offering of 9,660,000 American Depositary Shares ("ADSs", each representing ten (10) of its Ordinary Shares, at a public offering price of $2.50 per ADS, for gross proceeds of approximately $24.1 million. All of the ADSs in the offering were sold by BioLineRx. The amount of ADSs sold includes an additional 1,260,000 ADSs purchased by the underwriters pursuant to the over-allotment option granted to them by BioLineRx.

OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.

Portola Pharmaceuticals (PTLA) Jumps: Stock Up 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:51AM CST
Portola Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 8% on the day.

BioLineRx to Present at the Annual ROTH Growth Stock Conference in California
Business Wire - Wed Mar 05, 6:03AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 26th Annual ROTH Growth Stock Conference being held at the Ritz Carlton in Dana Point, CA.

Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:39AM CST
Nektar Therapeutics was a big mover last session, as its shares rose nearly 11% on the day.

BioLineRx Prices $21.0 Million Underwritten Public Offering of its American Depositary Shares
Business Wire - Tue Mar 04, 8:07AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has priced an underwritten public offering of 8,400,000 American Depositary Shares ("ADSs", each representing ten (10) of its Ordinary Shares, at a public offering price of $2.50 per ADS for gross proceeds of $21.0 million. All of the ADSs in the offering are to be sold by BioLineRx. Delivery of the ADSs is expected to occur on March 7, 2014. BioLineRx has granted the underwriters a 30-day option to purchase up to an additional 1,260,000 ADSs to cover over-allotments, if any.

Can Auxilium Pharma (AUXL) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:30AM CST
Auxilium Pharma has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy.

BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
PR Newswire - Mon Mar 03, 3:35PM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has commenced an underwritten public offering of its American Depositary Shares ("ADSs", each representing ten (10) of its Ordinary Shares. All of the ADSs in the offering are to be sold by BioLineRx.

BioLineRx appoints Dr Sandra Panem to board
M2 - Tue Feb 25, 5:59AM CST
Biopharmaceutical company BioLineRx (NASDAQ:BLRX)(TASE:BLRX), headquartered in Israel, revealed on Monday the addition of Dr Sandra Panem PhD to its board of directors.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 49

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 139

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 93

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 63

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 110

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 69

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Products Secures $140 Million in NASA Liquid Hydrogen Contracts

Updated Category News Views 85

Air Products Receives Significant NASA Contracts Air Products, a leading supplier in the industrial gases market, recently announced an impressive contract award from NASA valued at over $140 million. This contract aims at supplying liquid hydrogen for various NASA facilities, most notably the renowned Kennedy Space Center and other significant sites where vital space...

Continue Reading
Navigating Market Realities: A Look Ahead for Investors

Updated Category News Views 158

The Uncomfortable Truth About Market Valuations Many investors may feel uneasy hearing this, but it’s essential to face the real data regarding market potential. After analyzing the last 40 years of market information from various developed economies, including movements in China, the reality might deter those banking on robust returns in the forthcoming decade. There's...

Continue Reading
Sodexo Unveils Its Universal Registration Document for 2025

Updated Category News Views 367

Introduction to Sodexo's Fiscal 2025 Document Sodexo has made significant strides in enhancing transparency and providing essential information through its recently filed Fiscal 2025 Universal Registration Document (URD). This document, which is now accessible to investors and stakeholders, showcases the company's ongoing commitment to accountability and sustainability....

Continue Reading
Paratus Energy's Q4 2025 Results: Key Indicators to Analyze

Updated Category News Views 197

Paratus Energy Services Ltd. (PLSV) is about to drop its unaudited interim Q4 2025 financial results on February 27, 2026. But here’s the kicker—traders are left with scant intel leading into this call, and that can rattle markets. First off, let’s talk about the earnings whispers. The usual playbook includes scouring through EPS projections and revenue figures, but...

Continue Reading
Keefe Adjusts Rating for Bank of N.T. Butterfield Amid Challenges

Updated Category News Views 72

Keefe Downgrades the Bank of N.T. Butterfield Stock Rating Recently, Keefe, Bruyette & Woods revised its recommendation for Bank of N.T. Butterfield (NYSE: NTB) stock, shifting the rating from Outperform to Market Perform. The price target has also been adjusted from $44 to $41. This reflects the bank's forecast of significant net interest income (NII) challenges...

Continue Reading